Effects of different concentrations of irbesartan on the differentiation and mineralization of preosteoblasts

doi:10.3969/j.issn.2095-4344.2017.04.002

Abstract

Abstract:

Abstract
BACKGROUND: Angiotensin II receptor antagonists have been found to exerct a stronger protective effect on bone than angiotensin converting enzyme inhibitors.
OBJECTIVE: To investigate the effect of different concentrations of irbesartan (angiotensin II receptor antagonist) on the differentiation and mineralization of mouse preosteoblasts.
METHODS: Mouse preosteoblast cell lines MC3T3-E1 in logarithmic phase were selected and cultured in the osteogenic induction medium containing 0 (control group), 0.001, 0.01, 0.1 mmol/L irbesartan, respectively. Ten days later, the cell differentiation was observed by alkaline phosphatase staining. The mineralization was observed by alizarin red staining after 21 days of culture. mRNA expressions of osteocalcin, alkaline
phosphatase and Runt-associated transcription factor 2 in osteoblasts were detected by real-time PCR at 1, 4, 7, 14 and 21 days of culture.
RESULTS AND CONCLUSION: The activity of alkaline phosphatase in all the irbesartan groups (0, 0.001, 0.01, 0.1) was higher than that in the control group (P < 0.05), which was the most obvious in 0.01 mmol/L. The number and area of calcium nodules in each irbesartan group were significantly higher than those in the control group (P < 0.05), especially in 0.01 mmol/L. Compared with the control group, 0.01 mmol/L irbesartan significantly upregulated the mRNA expressions of osteocalcin, alkaline phosphatase and Runt-associated transcription factor 2 (P < 0.05). These results suggest that 0.01 mmol/L irbesartan significantly promotes the differentiation and mineralization of osteoblasts.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Osteoblasts, Cell Differentiation, Alkaline Phosphatase, Tissue Engineering

CLC Number:

R318

Ding Xiao-wei1, Xu Yuan2, Min Ze1, Qian Yong-zhu1, He Zhi-dan1, Xu Yang1, Liu Qian-qian1, Zhao Zhong-hai1. Effects of different concentrations of irbesartan on the differentiation and mineralization of preosteoblasts[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(4): 499-504.

Figures/Tables 2

References

[1] Seo KW,Lee SJ,Ye BH,et al.Mechanical stretch enhances the expression and activity of osteopontin and MMP-2 via the Akt1/AP-1 pathways in VSMC.J Mol Cell Cardiol.2015;85:13-24.

[2] 李广悦,谢芸,岳源,等.血管紧张素Ⅱ对小鼠成骨细胞骨桥蛋白和基质金属蛋白酶2表达的影响[J].国际口腔医学杂志, 2013, 40(3):291-296.

[3] Resnick LM,Laragh JH,Sealey JE,et al.Divalent cations in essential hypertension. Relations between serum ionized calcium,magnesium,and plasma renin activity.N Engl J Med. 1983;309(19):888-891.

[4] Cappuccio FP,Kalaitzidis R,Duneclift S,et al.Unravelling the links between calcium excretion,salt intake,hypertension,kidney stones and bone metabo-lism.J Nephrol. 2000;13:169-177.

[5] Balcerzak M,Hamade E,Zhang L,et al.The roles of annexins andalkaline phosphatase in mineralization process.Acta Biochim Pol.2003;50(4):1019-1038.

[6] Siggelkow H,Rebenstorff K,Kurre W,et al.Development of theosteoblast phenotype in primary human osteoblasts in culture:comparison with rat calvarial cells in osteoblast differentiation.J Cell Biochem.1999;75(1):22-35.

[7] 代守前,施秀,韦永中,等.血清素对体外培养大鼠出骨细胞增殖分化和矿化功能的影响[J].中华创伤骨科杂志,2013,15(9): 784-789.

[8] Aubin JE.Advances in the osteoblast lineage．Biochem Cell Biol.1998;76(6):899-910．

[9] Sun YQ,Ashhurst DE.Osteogenic growth peptide enhances the rate offracture healing in rabbits.Cell Biol Int.1998;22(4): 313-319．

[10] Howlett CR,Cave J,Williamson M,et al.Mineralization in in vitro cultures of rabbit marrow stromal cells.Clin Orthop Relat Res.1986;(213):251-263．

[11] 董世武,应大君,段小军,等.核心结合因子a1对骨髓间充质干细胞成骨细胞标志基因表达的影响[J].中国修复重建外科杂志,2005, 19(9):746-750.

[12] Stein GS,Lian JB,van Wijnen AJ,et al.Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression.Oncogene. 2004; 23(24):4315-4329．

[13] Valenti MT,Dalle CL,Donatelli L,et al.Gene expression analysis in osteoblastic differentiation from peripheral blood mesenchymal stem cells.Bone.2008;43(6):1084-1092.

[14] Jensen ED,Nair AK,Westendorf J.Histone deacetylase co-repressor complex control of Runx2 and bone formation.CritRevEukaryotGene Expr.2004;17(3):187-196.

[15] Pelletier N,Champagne N,Stifani S,et al.MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2.Oncogene. 2002;21(17): 2729-2740.

[16] Hatton R,Stimpel M,Chambers TJ.Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro.J Endocrinol.1997; 152(1):5-10. [17] Lynn H,Kwok T,Wong SY,et al.Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese.Bone.2006;38584-588.

[18] Kwok T,Leung J,Zhang YF,et al.Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?Osteoporos Int.2012;23(8):2159-2167.

[19] Zhang YF,Qin L,Leung PC,et al.The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese.J Bone Miner Metab.2012;30(6):666-673.

[20] Kwok T,Leung J,Barrett-Connor E,et al.ARB users exhibit a lower fracture incidence than ACE inhibitor users among older hypertensive men.Age Ageing.2016.[Epub ahead of print]

[21] Butt DA,Mamdani M,Gomes T,et al.Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.J Bone Miner Res.2014;29(11): 2483-2488.

[22] Li EC,Heran BS,Wright JM.Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension.Cochrane Database Syst Rev.2014;(8): CD009096.

[23] Xue H,Lu Z,Tang WL,et al.First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.Cochrane Database Syst Rev. 2015;1:CD008170.

[24] Hsiao FC,Tung YC,Chou SH,etal.Fixed-Dose Combinations of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors.Medicine (Baltimore).2015;94(51):e2355.

[25] Roy J,Shah NR,Wood GC,et al.Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.J Clin Hypertens(Greenwich).2012; 14(7): 407-414.

[26] Pathak JV,Dass EE.A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.Indian J Pharmacol. 2015;47(2):148-152.